SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
WPI Analysis & Videos »
WPI: Bull or Bear?
BioMedReports: FDA Calendar Updates
WPI
|
|
|
+5.58%
in
118 days
<> Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 260 entries as of 7/15/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clini...
|
Bullish on WPI ...
WPI
|
|
|
+17.78%
in
188 days
Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products primarily in the United States. The company?s products are used in various therapeutic areas, including central nervous system, hormones and synthetic substitutes, cardiovascular, nephrology, gastrointestinal, and other areas. It operates in three segments: Generic, Brand, and Distribution. The Generic segment manufactures and sells generic products for various therapeutic classes comprising anti-depressant,...
|
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
WPI
|
|
|
+10.82%
in
84 days
(closed on 07/15/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Big Pharma Goes Generic
WPI
|
|
|
+0.57%
in
55 days
(closed on 04/22/09)
<> <> <> <> <> <>  Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
|
A 130/30 Pharma Trade
WPI
|
|
|
+1.21%
in
6 days
(closed on 02/26/09)
By Mike Havrilla on 2/20/09 ETF Innovators The tables at my website link below include 12 U.S. listed companies from the ETF Innovators Global Generic Drug Index along with seven brand drug companies, which are ranked in descending order based on their patent expiration exposure through the end of 2011 as a percentage of total trailing 12-month revenue. <> Investors who are bullish on the generic drug industry may consider implementing a 130/30 pharma trade by shorting any/all...
|
Updated Clinical Trial and FDA Calendar
WPI
|
|
|
+10.08%
in
23 days
(closed on 02/20/09)
Updated Clinical Trial and FDA Calendar The tables at my website link below feature an updated calendar of 78 expected FDA new product decisions and 92 pending clinical trial result estimates + pending FDA re-submissions or new submissions for regulatory approval. Click here for a link to my previous calendars and below is a summary of FDA and clinical trial news since my last article. <> 1.) Watson Pharma (WPI): WPI received FDA approval for Gelnique, which represents the ...
|
A New Index of Health Product Innovators
WPI
|
|
|
+3.10%
in
23 days
(closed on 01/28/09)
<> 
The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device.
The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi...
|
Teva Beats on Profits: A Biogeneric Boon in '09?
WPI
|
|
|
+7.25%
in
59 days
(closed on 01/05/09)
<> 
<> Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than dou...
|
A Bullish Outlook for Generic Drugs After Election
WPI
|
|
|
-9.26%
in
2 days
(closed on 11/06/08)
<> 
In addition to the favorable underlying trends I wrote about previously for the generic drug industry, both presidential candidates are bullish on the industry with the following excerpts taken directly from their websites:
Senator Obama : Lower drug costs by allowing the importation of safe medicines from other developed countries, increasing the use of generic drugs in public programs and taking on drug companies that block cheaper generic medicines from the market.
Senator McCain : R...
|
People Bullish on WPI
People Bearish on WPI
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About Watson Pharmaceuticals Inc.
- Answers.com
